(RS)-3-[(5-amino-6-chloropyrimidin-4-yl)amino]-1-N-tert-butyloxycarbonylpiperidine | 1271240-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (RS)-3-[(5-amino-6-chloropyrimidin-4-yl)amino]-1-N-tert-butyloxycarbonylpiperidine
• 英文别名: Tert-butyl 3-[(5-amino-6-chloropyrimidin-4-yl)amino]piperidine-1-carboxylate
• CAS: 1271240-32-4
• 化学式: C₁₄H₂₂ClN₅O₂
• 分子量: 327.814
• InChiKey: NJICQMVRAISFSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  乙酸二乙氧基甲酯 、 (RS)-3-[(5-amino-6-chloropyrimidin-4-yl)amino]-1-N-tert-butyloxycarbonylpiperidine 反应 32.0h， 以91%的产率得到(RS)-1-N-tert-butyloxycarbonyl-3-(6-chloropurin-9-yl)piperidine
  参考文献：
  名称：

  The synthesis of piperidine nucleoside analogs—a comparison of several methods to access the introduction of nucleobases

  摘要：

  This work deals with the synthesis of piperidine and hydroxypiperidine analogs of nucleosides. Starting from commercially available 3-hydroxypiperidine, proline or 4-hydroxyproline, a series of piperidine derivatives of both purine and pyrimidine nucleobases was prepared. Various methods of nucleobase attachment were evaluated. The prepared compounds were tested for cytostatic, antibacterial, and antiviral properties but no significant activity was found. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.12.029
• 作为产物：
  描述：

  3-羟基哌啶 在 4-二甲氨基吡啶 、 sodium azide 、 10% palladium on activated charcoal 、 氢气 、 碳酸氢钠 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 110.0 ℃ 、101.33 kPa 条件下， 反应 68.5h， 生成 (RS)-3-[(5-amino-6-chloropyrimidin-4-yl)amino]-1-N-tert-butyloxycarbonylpiperidine
  参考文献：
  名称：

  The synthesis of piperidine nucleoside analogs—a comparison of several methods to access the introduction of nucleobases

  摘要：

  This work deals with the synthesis of piperidine and hydroxypiperidine analogs of nucleosides. Starting from commercially available 3-hydroxypiperidine, proline or 4-hydroxyproline, a series of piperidine derivatives of both purine and pyrimidine nucleobases was prepared. Various methods of nucleobase attachment were evaluated. The prepared compounds were tested for cytostatic, antibacterial, and antiviral properties but no significant activity was found. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.12.029

文献信息

• BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3505171A1

  公开（公告）日：2019-07-03

  The present invention provides: a novel use of a specific bicyclic nitrogen-containing heterocyclic compound as a PDE7 inhibitor; a novel bicyclic nitrogen-containing heterocyclic compound having a PDE7 inhibitory effect, a method for producing the compound, a use of the compound, and a pharmaceutical composition containing the PDE7 inhibitor or the compound; and others. More specifically, the present invention provides a PDE7 inhibitor containing the compound represented by the formula (I): [wherein the symbols have the same meanings as those described in the description] or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了：一种特定含双环氮杂环化合物作为PDE7抑制剂的新用途；一种具有PDE7抑制作用的新型含双环氮杂环化合物、一种生产该化合物的方法、一种该化合物的用途以及一种含有该PDE7抑制剂或该化合物的药物组合物；以及其他。更具体地说，本发明提供了一种含有由式（I）代表的化合物的 PDE7 抑制剂： [其中符号的含义与描述中的符号相同]或其药学上可接受的盐作为活性成分的 PDE7 抑制剂。